Double threat: Ovarian cancer and thrombotic complications

Abstract

Currently, patients with cancer are undoubtedly more likely to develop thrombosis and thromboembolism. In some cases, symptoms of thrombotic complications could be the first signs of a malignant tumor. Thus, the treatment of such patients should follow two directions: treatment of cancer and maintenance therapy aimed at coagulopathy correction. Anticoagulant and antiplatelet therapies are high priorities in the treatment of these conditions; however, their adverse effects should not be forgotten–high risk of bleeding. There is a very fine line between the risks of thromboembolic complications and bleeding; both conditions can threaten the patient’s life. Thus, a multidisciplinary approach, timing, and balanced treatment can save patients’ lives.

Keywords

ovarian cancer / thrombotic complications / case report

References

[1] Lecumberri R, Marqués M, Panizo E, et al. High incidence of venous thromboembolism despite electronic alerts for thromboprophylaxis in hospitalised cancer patients. ThrombHaemost. 2013;110(1):184–190. doi: 10.1160/TH13-02-0131

[2] Lecumberri R., Marqués M., Panizo E., et al High incidence of venous thromboembolism despite electronic alerts for thromboprophylaxis in hospitalised cancer patients //ThrombHaemost. 2013. Vol. 110, N 1. P. 184–190. doi: 10.1160/TH13-02-0131

[3] Khorana AA. Risk assessment for cancer-associated thrombosis: what is the best approach? ThrombRes. 2012;129(1):S10-5. doi: 10.1016/S0049-3848(12)70009-9

[4] Khorana A.A. Risk assessment for cancer-associated thrombosis: what is the best approach? Thromb Res. 2012. Vol.129, N 1. P. S10–5. doi: 10.1016/S0049-3848(12)70009-9

[5] Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et al. ESC Scientific DocumentGroup. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). EurHeartJ. 2016;37(36):2768–2801. doi: 10.1093/eurheartj/ehw211

[6] Zamorano J.L., Lancellotti P., Rodriguez Muñoz D., et al. ESC Scientific Document Group. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC) // EurHeartJ. 2016. Vol. 37, N 36. P. 2768–2801. doi: 10.1093/eurheartj/ehw211

[7] Ter-Ovanesov MD. Tromboticheskie oslozhneniya v onkologii:opyt, realizovannyy na praktike / MD Ter-Ovanesov, AV Madzhuga. Prakticheskaya onkologiya . 2001;2(05):25–32.(In Russ).

[8] Тер-Ованесов М.Д. Тромботические осложнения в онкологии:опыт, реализованный на практике / М.Д. Тер-Ованесов, А.В. Маджуга // Практическая онкология. 2001. Т. 2, № 1(05). С. 25–32.

[9] Dammacco F, Vacca A, Procaccio P, et al. Cancer-related coagulopathy (Trousseau’s syndrome): review of the literature and experience of a single center of internal medicine. ClinExpMed. 2013;13(2):85–97. doi: 10.1007/s10238-013-0230-0

[10] Dammacco F., Vacca A., Procaccio P., et al. Cancer-related coagulopathy (Trousseau’s syndrome): review of the literature and experience of a single center of internal medicine // ClinExpMed. 2013. Vol. 13, N 2. P. 85–97. doi: 10.1007/s10238-013-0230-0

[11] Dvoretsky LI, Dyadkov IN, Stepanchenko AP, Dubrovskaya NV. Venous thromboembolism as the first manifestation of disseminated malignancy (Trussos syndrome). Bulletin of Siberian Medicine. 2019;18(3):232–237. (In Russ). doi: 10.20538/1682-0363-2019-3-232–237

[12] Дворецкий Л.И., Дядьков И.Н., Степанченко А.П., Дубровская Н.В. Венозный тромбоэмболизм как первая манифестация распространенного опухолевого процесса (синдром Труссо). Бюллетень сибирской медицины. 2019. Vol. 18, N. 3. P. 232–237. doi: 10.20538/1682-0363- 2019-3\-232–237

[13] Vorobev AV, Chabrov AM, Savchenko AA. Pathogenesis of Trousseau’s syndrome. Obstetrics, gynecologyandreproduction. 2015;9(2):99–109. (In Russ). doi: 10.17749/2070-4968.2015.9.2.099-109

[14] Воробьев А.В., Чабров А.М., Савченко А.А., и др. Вопросы патогенеза синдрома Труссо // Акушерство, гинекология и репродукция. 2015. Т. 9. № 2. С. 99–109. doi: 10.17749/2070-4968.2015.9.2.099-109

[15] Maximova MY, Smirnova IN, Loskutnikov MA. Paraneoplasticheskaya koagulopatiya kak prichina povtornykh narusheniy mozgovogo krovoobrashcheniya (kliniko-morfologicheskoe nablyudenie). Annals of Clinical and Experimental Neurology. 2013;7(1):39–44. (In Russ). doi: 10.17816/psaic245

[16] Максимова М.Ю, Смирнова И.Н., Лоскутников М.А., и др. Паранеопластическая коагулопатия как причина повторных нарушений мозгового кровообращения (клинико-морфологическое наблюдение) // Анналы клинической и экспериментальной неврологии. 2013. Т. 7, №1. C. 39–44. doi: 10.17816/psaic245

RIGHTS & PERMISSIONS

Mansurova A.S., Krasilnikov S.E., Voitcitckii V.E.